ArticleNeoplasia (New York, N.Y.)2014
Antitumor immunity induced after α irradiation.
Article in Neoplasia (New York, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 99 citations in OpenAlex.
- Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial.Journal for immunotherapy of cancer · 2025Trial
- Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.Cancer immunology research · 2024Trial
- Unlocking the therapeutic potential of immuno-radiotherapy: insights from preclinical and clinical research.Oncoimmunology · 2026Review
- A Scoping Review of the Challenges and Future Perspectives in the Use of Alpha-Emitters for Metastatic Ovarian Cancer.Molecules (Basel, Switzerland) · 2026Article
- Alpha particle therapy in glioblastoma: emerging biomarkers, mechanisms of response, and translational opportunities.Frontiers in oncology · 2026Review
- Combination therapy of anEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Targeted alpha therapy: a comprehensive analysis of the biological effects from "local-regional-systemic" dimensions.European journal of nuclear medicine and molecular imaging · 2025Review
- Assessing the radiation-induced bystander effect in radionuclide therapy using targeted radiopharmaceuticals.EJNMMI radiopharmacy and chemistry · 2025Article
- Anti-Tumor Immunization Efficacy after Particle-Radiation Exposure.Radiation research · 2025Article
- Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [Cancers · 2025Article
- Article
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- Exploring the therapeutic potential of localized alpha irradiation for cancer: from DNA damage to immune activation.BJR open · 2025Review
- Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment.Theranostics · 2025Review
- Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET).Npj imaging · 2024Review
- Radiation drives tertiary lymphoid structures to reshape TME for synergized antitumour immunity.Expert reviews in molecular medicine · 2024Review
- Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.EJNMMI radiopharmacy and chemistry · 2024Review
- Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice.EBioMedicine · 2024Article
- Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin's lymphoma.Exploration of targeted anti-tumor therapy · 2024Review
- Immunological effects of radiopharmaceutical therapy.Frontiers in nuclear medicine · 2024Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioimmunotherapy (RIT) is a therapeutic modality that allows delivering of ionizing radiation directly to targeted cancer cells. Conventional RIT uses β-emitting radioisotopes, but recently, a growing interest has emerged for the clinical development of α particles. α emitters are ideal for killing isolated or small clusters of tumor cells, thanks to their specific characteristics (high linear energy transfer and short path in the tissue), and their effect is less dependent on dose rate, tissue oxygenation, or cell cycle status than γ and X rays. Several studies have been performed to describe α emitter radiobiology and cell death mechanisms induced after α irradiation. But so far, no investigation has been undertaken to analyze the impact of α particles on the immune system, when several studies have shown that external irradiation, using γ and X rays, can foster an antitumor immune response. Therefore, we decided to evaluate the immunogenicity of murine adenocarcinoma MC-38 after bismuth-213 ((213)Bi) irradiation using a vaccination approach. In vivo studies performed in immunocompetent C57Bl/6 mice induced a protective antitumor response that is mediated by tumor-specific T cells. The molecular mechanisms potentially involved in the activation of adaptative immunity were also investigated by in vitro studies. We observed that (213)Bi-treated MC-38 cells release "danger signals" and activate dendritic cells. Our results demonstrate that α irradiation can stimulate adaptive immunity, elicits an efficient antitumor protection, and therefore is an immunogenic cell death inducer, which provides an attractive complement to its direct cytolytic effect on tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.